K-252A

K-252A

SCHEMBL13993461

COC(=O)[C@@]1(O)CC2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 9/20 1.00
PRKCQ Q04759 6/20 1.00
KDR P35968 6/20 1.00
MAP3K11 Q16584 6/20 1.00
MAP3K9 P80192 5/20 1.00
PRKD3 O94806 4/20 1.00
PRKCG P05129 4/20 1.00
PRKCB P05771 4/20 1.00
PRKCA P17252 4/20 1.00
PRKCH P24723 4/20 1.00
PRKCI P41743 4/20 1.00
PRKCE Q02156 4/20 1.00
PRKCZ Q05513 4/20 1.00
PRKCD Q05655 4/20 1.00
PRKD1 Q15139 4/20 1.00
MAP3K10 Q02779 4/20 1.00
MYLK Q15746 3/20 1.00
CDK4 P11802 2/20 1.00
CDK2 P24941 2/20 1.00
CAMKK2 Q96RR4 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
K-252A SCHEMBL29434956 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL31181849 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL29355962 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL13485248 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL15575821 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL24112155 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL13787898 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL968886 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL32665760 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9
K-252A SCHEMBL29660621 1.00 NTRK1 (1.00) NTRK1PRKCQKDRMAP3K11MAP3K9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019143971-A2 FORMULATIONS FOR DERMAL DELIVERY OF POLYMER CONJUGATES OF INDOLOCARBAZOLE COMPOUNDS WITH REDUCED EXPOSURE SIENNA BIOPHARMACEUTICALS, INC. (US) 2019-07-25 WO disclosed
US-20150209369-A1 COMBINATION THERAPY III TURUN YLIOPISTO (FI) 2015-07-30 US disclosed
US-20080299215-A1 DEUTERIUM-ENRICHED LESTAURTINIB PROTIA, LLC (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080299215-A1 DEUTERIUM-ENRICHED LESTAURTINIB DLST, ABL1, THPO NTRK1 3211/4885PRKCQ 3156/4885KDR 4028/4885
US-20150209369-A1 COMBINATION THERAPY III HDAC4, HDAC3, HDAC5 NTRK1 3707/4885PRKCQ 2351/4885KDR 3918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.